Business Wire

Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence

25.2.2026 15:00:00 CET | Business Wire | Press Release

Share

Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/

Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners.

“Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and their most complex challenges,” said Jeny Maier, managing partner of Axinn. “The addition of Dan, Katrina, and Jimmy reflects our strategic growth across high-stakes markets and reinforces our position as the premier antitrust practice in the country.”

Matheson served as Chief Trial Counsel at the FTC’s Bureau of Competition. A first-chair antitrust trial lawyer, he supervised and participated in all litigations conducted by the FTC's Litigation Group and advised leadership on case strategy and enforcement priorities. Matheson served as lead trial counsel in the FTC's landmark litigation against Meta Platforms, challenging the acquisitions of Instagram and WhatsApp. He also tried successful merger challenges and anticompetitive conduct cases for the FTC.

Rouse served as Chief of the Defense, Industrials and Aerospace Section, in addition to serving as Deputy Director of Civil Enforcement at the DOJ. She brings a decade of senior DOJ leadership experience, having shaped civil enforcement strategy and led merger and conduct investigations, monopolization matters, and enforcement actions across the healthcare, defense, industrials, and technology sectors.

“Dan's first-chair trial experience in several of the FTC's most significant tech merger and monopolization cases and Katrina's senior DOJ leadership across defense and aerospace position this group to win for clients navigating today's heightened enforcement environment,” said Mike Keeley, chair of Axinn's Antitrust practice.

“Katrina and Dan’s additions are particularly significant as we continue building our West Coast presence,” said Daniel Bitton, who heads Axinn’s West Coast practice. “Their deep expertise in the technology and defense sectors, along with their merger litigation and trial experience, make them critical additions for our clients across the region.”

Moore most recently served as a Trial Attorney at the DOJ, litigating merger challenges and conduct cases, including the Division's successful challenge to JetBlue's proposed acquisition of Spirit Airlines. He oversaw case strategy, trial work, and the management of large investigative teams.

“Jimmy's trial work on some of the DOJ's mostprominent airline and merger challenges reinforces Axinn's reputation as a go-to firm for clients who need seasoned litigators in the courtroom,” said Keeley. “Along with Dan and Katrina, this group represents exactly the talent we need to deliver results for clients at trial.”

Matheson, Rouse, and Moore join recent hires Jacklin Chou Lem and Mary Helen Wimberly as Antitrust partners, strengthening a partner group with depth of experience across trials, investigations, and merger enforcement.

About Axinn

Incisive. Inclusive. Invested. Inquisitive. We’re Axinn. Focusing on antitrust, intellectual property, and litigation, we make it our mission to understand your business, so we can anticipate every move. Acting with precision and conviction, we protect and accelerate your business growth, always thinking ahead.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260225403123/en/

Contacts

Julie Chodos
Chief Marketing & Business Development Officer
Axinn, Veltrop & Harkrider LLP
jchodos@axinn.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye